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Background: Due to the emergency of multidrug-resistant strains of Mycobacterium tuberculosis, is necessary the
evaluation of new compounds.
Findings: Tedizolid, a novel oxazolidinone, and ACH-702, a new isothiazoloquinolone, were tested against M. tuberculosis
infected THP-1 macrophages. These two compounds significantly decreased the number of intracellular mycobacteria at
0.25X, 1X, 4X and 16X the MIC value. The drugs were tested either in nanoparticules or in free solution.
Conclusion: Tedizolid and ACH-702 have a good intracellular killing activity comparable to that of rifampin or
moxifloxacin.
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Tuberculosis (TB) is a chronic respiratory disease that in
most cases is treatable and curable. Emergence of multi-
drug resistant TB strains (MDR), defined as those resist-
ant to at least rifampin and isoniazid, has been a public
health threat around the world. Recently, severe forms
of drug resistance, such as extensively drug-resistant
(XDR) TB, have been described. According to the WHO,
there were about 310,000 cases of MDR-TB among notified
patients with pulmonary TB in the world in 2011. Almost
60% of these cases were reported in India, China and the
Russian Federation. It is estimated that about 9% of MDR-
TB cases also had XDR-TB [1]. Given this increase in global
resistance, new compounds or new therapeutic schemes
are urgently needed.
Tedizolid phosphate (Trius Therapeutic Inc, San Diego
California) (formerly known as DA-7218, Dong-A Pharma-
ceutical Company, Ltd., Yongin, Korea) is a novel, potent
oxazolidinone pro-drug which is rapidly converted in vivo
to active tedizolid with antimicrobial effects. Tedizolid* Correspondence: carmelia7@hotmail.com
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article, unless otherwise stated.interacts with the bacterial 23S ribosome initiation complex
to inhibit translation, and is active against all clinically rele-
vant gram-positive pathogens, including linezolid-resistant
Staphylococcus aureus [2]. At present, this drug is in Phase
III clinical trials for treating acute bacterial skin and skin
structure infections with good results, similar to those ob-
tained with linezolid [3].
ACH-702 is a new isothiazoloquinolone that inhibits
bacterial DNA replication through inhibition of DNA
gyrase and topoisomerase IV. It has potent antibacterial
activity against a number of medically relevant bacteria,
including drug-resistant strains such as methicillin-resistant
S. aureus (MRSA) and vancomycin-resistant enterococci,
(VRE) [4-6]. Those two drugs have shown excellent in vitro
activity against susceptible and multidrug resistant M.
tuberculosis clinical isolates [7,8]. Drugs in tuberculosis
have to taken for months. Tedizolid belongs to the same
family of oxazolidinones as linezolid. Clinical experience
with the latter has shown the appearing of side effects, par-
ticularly mielossupression and peripheral neuropathy after
several months of application [9]. Quinolones, particularly
gatifloxacin, can produce disglicemias when is applied
chronically [10]. Given these data we wanted to evaluate
the possibility to use tedizolid or ACH-702 them inentral Ltd. This is an Open Access article distributed under the terms of the
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with less toxicity.
Nanoparticles have been proposed as an improved
system to carry and deliver drugs to a target organ and
have considerable potential for TB treatment [11]. Nano-
particles show advantages as drug carriers because of
high stability, capability to incorporate either hydrophilic
or hydrophobic compounds, and administration route
flexibility [11]. Hence, the main aim of this paper was to
determine the intracellular activity against M. tubercu-
losis of those two recently developed drugs: tedizolid
and ACH7-702 in two different forms: dissolved in
an adequate solvent and encapsulated in the synthetic,
biodegradable/biocompatible polymer; the poly-lactide-
co-glycolide (PLG), which has been approved by the US
FDA for human use [12].
Methods
Culture
M. tuberculosis H37Rv (ATCC 27294) strain was grown
on Lowenstein-Jensen media and then inoculated to li-
quid Middlebrook 7H9 medium for 7 days at 37°C. From
this culture, CFUs were quantitated by plating in Mid-
lebrook 7H10 agar.
Broth microdilution assay
Tedizolid Phosphate was donated by Sung-Hak Choi from
Dong-A Pharmaceutical Company, Ltd., Yongin, Korea,
while ACH-702 was obtained from Achillion Pharma-
ceuticals, Inc., New Haven. Stock solutions of 1 mg/ml
for moxifloxacin and tedizolid were dissolved in water,
ACH-702 was dissolved in dimethyl sulfoxide and ri-
fampin was dissolved in 95% ethanol. The Minimal
Inhibitory Concentration (MIC) for each drug was de-
termined using the broth microdilution method with
Alamar Blue [13]. In brief, mycobacterial suspensions
were prepared in 0.04% (vol/vol) Tween 80–0.2% bo-
vine serum albumin so their turbidities equaled a
McFarland turbidity standard of 1. Suspensions were
further diluted 1:25 in 7H9GC broth. The rest of the
technique was performed as published before [13]. The
MIC was defined as the lowest drug concentration
which prevented a color change of blue to pink. MICs
determined of each drug were: rifampin: 0.125 μg/ml,
moxifloxacin: 0.125 μg/ml, ACH-702: 0.063 μg/ml and
Tedizolid: 1.0 μg/ml.
Preparation of PLG-nanoparticles
Drug-loaded PLG-nanoparticles were prepared by the
multiple emulsion and solvent evaporation technique de-
scribed previously [14-17]. Briefly, 10 mg of drug and
10 mg of PLG were dissolved in distilled water, and then
added to dichloromethane (DCM) [water/DCM 1:10 (v/v)]
to a final volume of 10 ml. The mixture was sonicated for1 min to form the primary emulsion, which was poured
into 1% (w/v) aqueous polyvinyl alcohol and re-sonicated
for 3 min. The secondary emulsion formed was stirred
overnight and centrifuged at room temperature (8,000–
10,000 rpm for 15 min) to remove DCM and to harvest the
nanoparticles, which were washed three times with distilled
water and finally resuspended with 5 ml of water.
Quantification of PLG-nanoparticles
In order to quantify the encapsulated drug, an aliquot of
100 μl was diluted in 900 μl of 5% (w/v) SDS in 0.1 M
NaOH (lysis reagent) for 30 min at 50°C to release the
encapsulated drugs. The drugs were quantitated using a
Beckman DU-7500 UV-Visible, Scanning Spectropho-
tometer (Brea, California, USA), using 486 nm as the de-
tection wavelength for rifampicin and 286 nm as the
detection wavelength for the rest of antimicrobials using
lysis reagent as blank and the standards as controls. An-
timicrobials in nanoparticle form and free in solution
were prepared from the stock solution to final concen-
trations of 0.25X, 1X, 4X and 16X of the MIC previously
determined.
Drug cytotoxicity assay
In order to test the effect of drugs over THP-1 cells an
assay for cytotoxicity was carried on. THP-1 cells were
transformed to macrophages as described previously
[18] and then incubated at concentrations 16X the MIC
for M. tuberculosis H37Rv (ACH-702: 2 μg/ml, Tedizo-
lid: 8 μg/ml, Rifampicin: 15 μg/ml and Moxifloxacin:
8 μg/ml). After 12 h exposure (time used in posterior ex-
periments) viability was assessed using the crystal violet
technique [18,19]. In all cases cell viability after drug
treatment was greater than 98%.
Intracellular antibacterial assays
Intracellular antibacterial assays were done according to
the technique previously reported [20] as follows: before
the beginning of the experiment, bacteria were thawed
at 37°C and adjusted to 4 × 105 bacteria per milliliter
with RPMI-1640 medium; the monolayers were infected
at a multiplicity of infection of 1:10 (cells:bacilli) and in-
cubated for 6 h at 37ºC in a humid atmosphere with 5%
CO2. In order to remove the extracellular bacteria, cul-
tures were washed twice with pre-warmed PBS at 37ºC
and then 1 ml of amikacin (200 μg/ml) was added to
each well followed by incubation under the same condi-
tions as above for 2 h. The wells were washed twice with
PBS and 1 ml of RPMI-1640 containing the drug in solu-
tion or encapsulated to be tested was added, and the
plate was incubated for 12 h. After the pulse of antimi-
crobials, they were removed from the wells and 1 ml
RPMI-1640 was added. Three wells were used to quanti-
tate the initial CFUs by agar plating and the rest of the
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incubation time, bacterial counts were determined from
each well by agar plating as before. Plates were incu-
bated at 37ºC for 7 to 10 days until colonies were visible.
Data were evaluated with ANOVA variance for multiple
comparisons test.
Results and discussion
The intracellular antimicrobial activity of tedizolid and
ACH-702 against M. tuberculosis was assessed using the
THP-1 monocytic cell line since it has been a reliable
model to examine intracellular infection with M. tuber-
culosis [20]. As shown in Figure 1, tedizolid and ACH-702
each dramatically decreased the number of intracellular
mycobacteria 72 h after the infection compared with the
control when they were exposed to concentrations 0.25 X,
1 X, 4X and 16X MICs for the nanoparticulated form
(NP) and 0.25X and 1X MICs for the free solution (SOL)
(p < 0.0001). ACH -702 treatment led to a reduction of 1.4
LOG10 UFC/ml and tedizolid decreased bacterial counts
1.3 LOG. This activity can be comparable to that elicited by
two antibiotics with proven activity against tuberculosis,
moxifloxacin (reduced 1 LOG) and rifampicin (reduced 1.4ACH-702
Moxifloxacin
Figure 1 THP-1 cells infected with Mycobacterium tuberculosis H37Rv to a
drugs in solution (0.25X and 1X MICs) and nanoparticles (0.25X, 1X, 4X an
were lysed and plated on 7H10 to determine CFU/ml. Plots detail the bactericid
represent means ±1 standard error of the means.LOG). Rifampicin is still used as part of the first line drug
regimen due to sterilizing activity against non-dividing bac-
teria and moxifloxacin is one of the drugs being analyzed as
part of the second line TB drugs because of its low CMI
and a rapid sterilization activity on mycobacteria [21,22].
Since we previously eliminated extracellular bacteria with
amikacin in our assay, the antibacterial activity of Tedizolid
and ACH-702 was intracellular. This result is promising on
the possible use of these drugs during active infection.
A strategy to specifically deliver chemotherapeutic com-
pounds formulated in nanoparticles to target disease sites
has been discussed over the last two decades [23]. Several
drug carriers made of biocompatible and biodegradable
materials have been used including polymeric nanoparti-
cles, where the drug is attached, entrapped or encapsulated
in polymeric core and, depending upon the method of
preparation, they are designated as nanoparticles, nano-
spheres or nanocapsules [24].
Under nanoparticle format isoniazid, rifampicin, pyrazi-
namide, moxifloxacin and econazole have been prepared
and administrated by gavage, subcutaneous and pulmonary
route to murine and guinea pig models of tuberculosis [23].
In all the studies made so far, nanoparticles produced moreTedizolid
Rifampicin
M.O.I.: 1:10 (cells:bacilli) were subjected to several concentrations of
d 16X MICs) in triplicate as described. After 72 h post infection, cells
al activity of ACH-702, Tedizolid, Moxifloxacin and Rifampicin. Values
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and also less doses of nanoparticle form were sufficient to
achieve bacterial clearance and in some cases resulted in
complete sterilization [23]. In our study, there was not a
significant difference in the antimicrobial activity between
drug in solution and nanoparticles probably due to the high
efficacy exhibited by drugs at low concentrations.
Conclusions
Mycobacterium tuberculosis is a bacteria living preferen-
tially inside the cells. One step ahead in research of anti-TB
drugs is to evaluate their intracellular activity against the
bacilli. In this paper we have described a suitable assay in
THP-1 macrophages to study anti-tuberculosis compounds
on intracellular bacteria. We found that both drugs tedizo-
lid and ACH-702 had a comparable activity to that elicited
by rifampin and moxifloxacin. However we did not find dif-
ferences if the compounds were in solution or encapsulated
in PLG. Further studies on these drugs should consider
using an in vivo animal model to explore their possibility as
anti-tuberculosis therapy.
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